Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth (Q39472261)
Jump to navigation
Jump to search
scientific article published on 16 September 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth |
scientific article published on 16 September 2011 |
Statements
1 reference
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth (English)
1 reference
F Michael Yakes
1 reference
Jason Chen
1 reference
Jenny Tan
1 reference
Kyoko Yamaguchi
1 reference
Yongchang Shi
1 reference
Peiwen Yu
1 reference
Fawn Qian
1 reference
Felix Chu
1 reference
Frauke Bentzien
1 reference
Belinda Cancilla
1 reference
Jessica Orf
1 reference
Andrew You
1 reference
A Douglas Laird
1 reference
Stefan Engst
1 reference
Lillian Lee
1 reference
Justin Lesch
1 reference
Yu-Chien Chou
1 reference
Alison H Joly
1 reference
16 September 2011
1 reference
1 reference
2298-2308
1 reference
Identifiers
1 reference